TD Cowen Starts Coverage on Akoustis Technologies, Citing Radiopharmaceutical Potential
TD Cowen has launched coverage of Akoustis Technologies (AKTS) with a Buy rating, drawing attention to the company’s miniprotein platform and early tumor-targeting data for pipeline candidates. The research note projects more than $5 billion in combined sales by 2035 for two lead constructs, while market metrics and fair-value estimates suggest the…